Stoney, FNKO and MAT are killing it! I want to buy more on a pullback, I collect anime and cartoon bobble and action figures.Well I guess you hold something two F ing years good things happen.
FNKO
21.19 +4.47 (+26.73%)<----
After hours: 4:53PM
GBA Presents: THE BARE ESSENTIALS
- Thread starter stonedinvestor
- Start date
Trying a after shock BROS energy drink, twenty cars deep. Busy while SBUX not so much. Good investment Stoney?
Twenty cars deep says a lot about how good their product tastes... but 20 cars deep is 20 cars deep, and again, I go back to their latest report, and organic sales are forecast to be in the low-mid single digits.
That's horrible, I mean it's to be expected out of someone like Darden, but this is a growth story.
There is no coffee in the world that's worth a 20 car deep line. For me at least.
Maybe CMG will buy them and show them how to run the operation.
Now that said, East of the Mississippi, if it's as good as everyone says, new store growth is there. and those new stores will in fact experience huge yoy growth. For a few years at least. Then comes that 20 car line.
There's certainly something to be said about a best in class product, and apparently BROS has one.
Tough call on this one. But like I told Stoney, when CMG was at this early stage of their development, it was 30%+ same store sales quarter after quarter after quarter. And it kinda still is every now and then. OK, mid-teens... but still.
Where's that picture I posted for Stoney?
Edit> Here.
https://elitetrader.com/et/threads/gba-presents-the-bare-essentials.365622/page-37#post-5565653
Not kidding Van, there are four BROS I know of and the one closest has ten cars waiting during slow times. The only restaurant exceeding them is Chick-Filet, line gets to forty cars blocking traffic. In-Out is bad too.
Chick-Fil kills it, it’s gold!
Ted.... I have a concept for the new format--
TED TALKS..... A Wrap Up Of Wrap ups....
There was a very large brand study and the no 1 food choice for loyalty is Chic Filet.
stonedinvestor said:
The rain is cumming down ... You might want to clear those cookies in your browser's spell-checker.
Yes that was an unfortunate error. I am a phonetic speller which can cause problems!
TED TALKS..... A Wrap Up Of Wrap ups....
There was a very large brand study and the no 1 food choice for loyalty is Chic Filet.
stonedinvestor said:
The rain is cumming down ... You might want to clear those cookies in your browser's spell-checker.
Yes that was an unfortunate error. I am a phonetic speller which can cause problems!
- This week's oil price advance - the third out of the past four - came despite lingering concerns that COVID-19 lockdowns in China will hurt consumption.
- "Crude prices just want to head higher as energy traders completely fixate over the looming European sanctions on Russian oil," Oanda's Edward Moya said. "No one wants to be on the wrong side of a major crude supply disruption headline, so whatever oil price dips that happen will be short-lived."
- "Fundamentals for oil are bullish, and it is only fears of an economic slowdown in the future that is holding us back," according to Price Futures Group's Phil Flynn.
- In a sign of how well things are going for oil and gas companies, EOG Resources (EOG), which surged 7% on Friday and 16% for the week, introduced a shareholder framework with expectations to return at least 60% of annual free cash flow to its investors.
Moderna (NASDAQ:MRNA) filed a motion to dismiss a lawsuit filed by two small biopharma companies seeking damages for violation of certain U.S. patents related to the company’s blockbuster COVID-19 shot, branded as Spikevax.
RNA therapeuticscompany Genevant Sciences and clinical-stage biotech Arbutus Biopharma (ABUS) filed the case in February, holding Moderna (MRNA) and an affiliate of the vaccine makeraccountable for the infringement.
“The claims brought by Genevant and Arbutus are unfounded because Moderna’s COVID-19 vaccine does not infringe any valid patents,” Moderna (MRNA) saidin a statementafter filing the motion in a federal court in Delaware on Friday.
The company said in the new filing that it sought to dismiss the claims because Genevant and Arbutus (ABUS) “have sued the wrong party in the wrong court.”
Instead, Moderna (MRNA) said that, under federal law, the patent holders seeking claims against the government-contracted suppliers must sue the government in the U.S. Court of Federal Claims.
“This law provides an important statutory protection for authorized government suppliers and played a critical role in encouraging companies, including Moderna, to step up and help the Government fight the COVID-19 pandemic,” the company added.
During the pandemic, the U.S. government was the only buyer of the mRNA-based COVID-19 shot developed by Moderna (MRNA) in partnership with the National Institutes of Health (NIH).
Even if Genevant and Arbutus (ABUS) were to refile in the U.S. Court of Federal Claims, their claims would fail as the company had not infringed any patents, Moderna (MRNA) said.
In response, Genevant said it would object to Moderna’s (MRNA) motion. “Rather than respond to the substance of our claims, Moderna is trying to shift responsibility for its patent infringement to the U.S. taxpayer,”The WallStreet Journalreported, quoting Genevant.
Last year, in a U.S. patent application for its vaccine, the Cambridge, Mass.-based Moderna (MRNA) dropped three NIH scientists and listed only its employees as inventors of a key component of the shot.
Later, the company pulled the application after NIH director Dr. Francis Collins said theagency would defend its claims.
RNA therapeuticscompany Genevant Sciences and clinical-stage biotech Arbutus Biopharma (ABUS) filed the case in February, holding Moderna (MRNA) and an affiliate of the vaccine makeraccountable for the infringement.
“The claims brought by Genevant and Arbutus are unfounded because Moderna’s COVID-19 vaccine does not infringe any valid patents,” Moderna (MRNA) saidin a statementafter filing the motion in a federal court in Delaware on Friday.
The company said in the new filing that it sought to dismiss the claims because Genevant and Arbutus (ABUS) “have sued the wrong party in the wrong court.”
Instead, Moderna (MRNA) said that, under federal law, the patent holders seeking claims against the government-contracted suppliers must sue the government in the U.S. Court of Federal Claims.
“This law provides an important statutory protection for authorized government suppliers and played a critical role in encouraging companies, including Moderna, to step up and help the Government fight the COVID-19 pandemic,” the company added.
During the pandemic, the U.S. government was the only buyer of the mRNA-based COVID-19 shot developed by Moderna (MRNA) in partnership with the National Institutes of Health (NIH).
Even if Genevant and Arbutus (ABUS) were to refile in the U.S. Court of Federal Claims, their claims would fail as the company had not infringed any patents, Moderna (MRNA) said.
In response, Genevant said it would object to Moderna’s (MRNA) motion. “Rather than respond to the substance of our claims, Moderna is trying to shift responsibility for its patent infringement to the U.S. taxpayer,”The WallStreet Journalreported, quoting Genevant.
Last year, in a U.S. patent application for its vaccine, the Cambridge, Mass.-based Moderna (MRNA) dropped three NIH scientists and listed only its employees as inventors of a key component of the shot.
Later, the company pulled the application after NIH director Dr. Francis Collins said theagency would defend its claims.
UPST earn Monday---short interest of 26%